Search
Dihydroergocristine
go.drugbank.com/drugs/DB13345Approved[A32879] To know more about ergoloid mixtures, please visit [DB01049]. … Dihydroergocristine is part of the ergoloid mixture products.[L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.
Paraldehyde
go.drugbank.com/drugs/DB09117ApprovedWithdrawnParaldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. … It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties.
Magnesium gluconate
go.drugbank.com/drugs/DB13749ApprovedWithdrawnAlthough magnesium is available in the form of sulphates, lactate, hydroxide, oxide and chloride, only magnesium gluconate is recommended for magnesium supplementation as it appears to be better absorbed … Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an ingredient in some medicines (such as antacids
Dexibuprofen
go.drugbank.com/drugs/DB09213ApprovedWithdrawnIt is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. … Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved oral bioavilability [A19259].
DaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational[L47865] On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. … [A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigationala procedure by increasing platelet counts to the optimal level ≥50,000 per microliter. … decreasing the need for blood transfusions.
Categories: Thrombopoietin Receptor AgonistErdosteine
go.drugbank.com/drugs/DB05057ApprovedInvestigationalErdosteine has been shown to be safe and well tolerated in clinical trials. … Co-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier
Larotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigationalIt was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847]. On April 10, 2025, the FDA granted full drug approval.[L52805] … [L49821] Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition
Categories: Tropomyosin Receptor Kinases InhibitorsProducts: VITRAKVI®CÁPSULAS DE 100MGNilutamide
go.drugbank.com/drugs/DB00665ApprovedInvestigationalProstate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration. … Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue.
Categories: Androgen Receptor Antagonists, Androgen Receptor InhibitorsEthotoin
go.drugbank.com/drugs/DB00754ApprovedThe latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. … The mechanism of action is probably very similar to that of phenytoin.